

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|---|
| (51) International Patent Classification ⁶ : C07D 491/056, A61K 31/55 | | A1 | (11) International Publication Number: WO 95/01357 |
| | | | (43) International Publication Date: 12 January 1995 (12.01.95) |
| (21) International Application Number: PCT/HU94/00024 | | (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 30 June 1994 (30.06.94) | | | |
| (30) Priority Data: P 93 01922 2 July 1993 (02.07.93) HU | | | |
| (71) Applicant (for all designated States except US): GYÓGYSZERTUDATÓ INTÉZET KFT. [HU/HU]; Berlini u. 47-49, H-1045 Budapest (HU). | | Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): LING, István [HU/HU]; Álmos vezér u. 44, H-1141 Budapest (HU). HÁMORI, Tamás [HU/HU]; Amfiteátrum u. 27, H-1031 Budapest (HU). BOTKA, Péter [HU/HU]; Harrer P. u. 18, H-1033 Budapest (HU). SÓLYOM, Sándor [HU/HU]; Fehérvári u. 111, H-1149 Budapest (HU). SIMAY, Antal [HU/HU]; Pagony u. 30, H-1124 Budapest (HU). MORAVCSIK, Imre [HU/HU]; Mester u. 38, H-1095 Budapest (HU). | | | |
| (74) Agent: DANUBIA; Bajcsy-Zsilinszky út 16, H-1051 Budapest (HU). | | | |
| (54) Title: OPTICALLY ACTIVE 1-(4-NITROPHENYL)-4-METHYL-7,8-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE AND PROCESS FOR PREPARING SAME | | | |
| (57) Abstract | | | |
| <p>The invention relates to the (+)- and (-)-enantiomers of the compounds of formula (I) as well as a process for the preparation of these enantiomers. This process comprises reducing 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine of formula (II) by using an adduct formed from an (R)- or (S)-, respectively, 2-amino-1,1-diphenyl-alkan-1-ol derivative of general formula (III), wherein R₁ and R₂, which are different, stand for a straight or branched chain C₁₋₄ alkyl group or an unsubstituted phenyl or benzyl group, with one molar equivalent of borane or a borane complex. The enantiomers of the compound of formula (I) are valuable intermediates in the synthesis of therapeutically active compounds.</p> | | | |
| | | | |
| | | (I) | |
| | | | |
| | | (II) | |
| | | | |
| | | (III) | |

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

- 1 -

OPTICALLY ACTIVE 1-(4-NITROPHENYL)-4-METHYL-7,8-
-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE AND
PROCESS FOR PREPARING SAME

5 This invention relates to the enantiomers of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of the formula (I)



and a process for the preparation of these enantiomers, which are valuable intermediates in the synthesis of therapeutically useful substances.

20 It is known from the Hungarian patent specifications Nos. 198,494 and 206,719 as well as from the published European patent application No. 492,485 and from publications [Bioorg. Med. Chem. Lett. 3, 99 (1993); Eur. J. Pharm. 224, 293 (1993)] that 1-(4-aminophenyl)-3-
25 -acyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepines, e.g. the 1-(4-aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine and 1-(4-aminophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine, possess anticonvulsive, muscle relaxant and
30 neuroprotective effects. The basis of these valuable pharmacological effects is a noncompetitive antagonism of quisqualate/AMPA receptors. Furthermore, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-
35 -benzodiazepine and 1-(4-acetylaminophenyl)-4-methyl-7,8-

- 2 -

-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine are dopamine-uptake-inhibiting and psychostimulatory in their character; therefore, these compounds may potentially be useful for the treatment of parkinsonism.

5 These compounds have chiral structure. As a result of their synthesis described earlier they are formed as racemates from a common intermediate, namely, from the racemic 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of formula (I).


10 It is known that the pure enantiomers of biologically active compounds may be very different from the viewpoint of both their main biological effects as well as toxicity, pharmacokinetics and metabolism. Thus, in the development of novel drugs it is aimed to prepare
15 optically pure enantiomers and some official prescriptions are directed to the same purpose [see e.g.: Development of Chiral Drugs in an Evolving Regulatory Environment. Regulatory Affairs 3, 483 (1991)].

 Although the racemic active compounds listed above
20 and their precursors having a racemic structure can in principle be resolved by using traditional methods, the most preferred possibility of preparing optically pure enantiomers consists in that the enantiomers of the first chiral molecule of the synthesis, in the given case the
25 compound of formula (I), are prepared and the subsequent steps of the synthesis are carried out by starting from these enantiomers. Whereas the traditional resolution based on the separation of diastereomeric salt or compound pairs can theoretically provide the pure
30 enantiomers of a racemic compound in a yield of at most 50%, by using an enantioselective chemical reaction in the step resulting in the development of chirality, the desired enantiomer(s) can be prepared in yields substantially higher than 50 %.

35 Thus, the invention is aimed at providing a

- 3 -

process, by which the double bond in 3,4-position of the achiral derivative of formula (II)



(II)

can enantioselectively be reduced to obtain in this way the enantiomers of the compound of formula (I) in a high yield and high optical purity.

Some methods are known in the literature for the enantioselective reduction of imino compounds. According to one of these methods the reduction is carried out by using diphenylsilane or hydrogen in the presence of complexes or transition metal salts formed with optically active tertiary phosphine ligands as homogeneous catalysts [Tetrahedron Letters 49, 4865 (1973); Angew. Chem. Int. Ed. Engl. 24, 995 (1985); J. Chem. Soc. Chem. Comm. 6 (1975); Tetrahedron: Asymmetry 4, 215 (1993)].


Other authors use a chiral triacyloxy borohydride as reducing agent for enantioselective reductions, where the chiral reducing reagent is most frequently prepared from N-acylproline and sodium borohydride *in situ* [Tetrahedron Letters 22, 3869 (1981); J. Chem. Soc. Perkin Trans. I, 265 (1983); Chem. Pharm. Bull. 31(1), 70 (1983); Heterocycles 29, 1283 (1989); J. Het. Chem. 28, 329 (1991)]. According to an other method reductive complexes formed from optically active 1,2-aminoalcohols and 2 molar equivalents of borane are useful for enantioselective reductions [J. Chem Soc. Perkin Trans. I, 2039 (1985); *ibidem* 3200 (1990); Tetrahedron: Asymmetry 3, 337

- 4 -

(1992)).

Each of the above methods have been used for specific individual groups of imino compounds; moreover, within these groups the enantiomeric purity of the primary products was strongly dependent on the substituents of the given imino compound.

Surprisingly, it has been found that 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine of formula (II) can enantioselectively be reduced by using in a small excess an adduct formed from a 2-amino-1,1-diphenylalkane-1-ol of the general formula (III),



having R or S configuration, respectively, with 1 molar equivalent of borane or a borane complex and in this way, 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of formula (I) can simply be prepared in a good yield with a high enantiomeric purity.

According to the invention, the preparation of enantiomers of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of formula (I) comprises reducing 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine of formula (II) by using an adduct formed from an (R)- or (S)-, respectively, 2-amino-1,1-diphenylalkane-1-ol derivative of formula (III), wherein

R_1 and R_2 , which are different, stand for hydrogen; a straight or branched chain C_{1-4} alkyl group; or an unsubstituted phenyl or benzyl group, with one molar equivalent of borane or a borane complex.

- 5 -

As mentioned above, the enantiomers of the compound of formula (I) are valuable intermediates which, after acylation and subsequent reduction, lead to the enantiomers of 1-(4-aminophenyl)-3-acyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepines, which are antagonists of the quisqualate/AMPA receptors; or, by reducing and then, if desired, acetylating the enantiomers of the compound of formula (I), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine and 1-(4-acetylaminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine can be obtained, which have psychostimulant character.

According to a preferred embodiment of the process of the invention the (R)- or (S)-1,2-aminoalcohol, respectively, of general formula (III), wherein R_1 and R_2 are as defined above, is dissolved in anhydrous methylene chloride or in a higher aliphatic halohydrocarbon and reacted with 1 molar equivalent of borane at a temperature between 0 °C and -70 °C, then left to stand at a temperature between 0 °C and 10 °C for 15 to 20 hours and finally the reductive complex obtained is reacted with the compound of formula (II) preferably dissolved in the same anhydrous solvent at a temperature between 0 °C and the boiling point of the solvent, preferably between 25 °C and 60 °C. The reaction mixture is suitably worked up as follows: the mixture is mixed with sodium carbonate solution, the organic phase is washed with water until neutral and evaporated under reduced pressure. The crystalline product obtained is suspended in a C_{1-3} alcohol, preferably ethanol, and the product is isolated by filtration.

The primary product obtained is characterized by its specific rotary power. The enantiomeric purity of the product is qualified by the percentage of enantiomers, which can be determined by the following methods:

- 6 -

- 1) by ^1H -NMR techniques using a complex of paramagnetic rare earth element (shift reagent); or
- 2) by high pressure liquid chromatography (HPLC) on a column containing a chiral sorbent.

5 According to our investigations, the primary product has a high enantiomeric purity, which can be increased nearly to 100% even by a single recrystallization.

10 The preparation of 5H-2,3-benzodiazepine derivative of formula (II) used as starting substance in the process according to the invention is described in the Hungarian patent specification No. 191,702. The 1,2-aminoalcohols of general formula (III) are known compounds, which can be synthesized on the basis of literature references [J. 15 Org. Chem. 49, 555 (1984); J. Chem. Soc. Perkin Trans. I, 2039 (1985); and Japanese patent specification No. 81-65,847 (Chem. Abstr. 95, 203530g)].

 The invention is illustrated in detail by the following non-limiting Examples.

20 **Example 1**

(-)-1-(4-Nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

Method A

25 To a solution containing 4.75 g (18.6 mmol) of (S)-(-)-2-amino-1,1-diphenyl-3-methylbutan-1-ol in 50 ml of anhydrous methylene chloride, 9.5 ml (17 mmol) of an 1.8 M tetrahydrofuran solution of borane-tetrahydrofuran complex were dropwise added at -70 °C under dry nitrogen in 20 minutes. The temperature of the solution was 30 gradually increased to 0 °C during 3 hours and then maintained at 4 °C for 15 hours.

 A solution containing 5.0 g (15.5 mmol) of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine in 100 ml of dry methylene chloride was drop- 35 wise added to the above solution at room temperature

- 7 -

during one hour while stirring. After allowing the reaction mixture obtained to stand at room temperature for 10 days, 10% aqueous sodium carbonate solution was added and the mixture was stirred for 30 minutes. The
5 organic phase was separated, washed twice with 50 ml of water each, dried over anhydrous sodium sulfate and evaporated under reduced pressure. After suspending the crystalline residue in 50 ml of ethanol, the orange-yellow crystals were filtered, washed twice with 5 ml of
10 ethanol each and dried at 50 to 60 °C to obtain 4.47 g (88.6%) of product, $[\alpha]_D^{25} = -118^\circ$ (c = 1, chloroform).

The ratio of (-) enantiomer to the (+) enantiomer was found to be 90:10 as determined by $^1\text{H-NMR}$ spectroscopy by using $\text{Eu}(\text{hfc})_3$ shift reagent (by weighing 5 mg
15 of shift reagent to 10 mg of substance and dissolving this mixture in deuteriochloroform).

After dissolving in 54 ml of hot ethyl acetate, the primary product was allowed to crystallize at room temperature for 15 hours. The crystalline precipitate was
20 filtered, washed 3 times with 5 ml of ethyl acetate each and dried at 50 to 60 °C to obtain 2.87 g (56.9%) of the aimed compound, $[\alpha]_D^{25} = -155.6^\circ$ (c = 1, chloroform), m.p.: 171-172.5 °C. On investigating the ratio of enantiomers, the amount of the minor enantiomer was found
25 to be lower than 1 % as determined by using either $^1\text{H-NMR}$ spectroscopy or simultaneously HPLC analysis [CHIRALCEL OJ. (Daicel Chemical Industries, LTD)] with a 35:65 mixture of hexane and isopropanol as eluent.

Method B

30 The method A of Example 1 was followed, with the difference that the reaction mixture was boiled under reflux for 3 days to give 4.27 g (84.7 %) of product, $[\alpha]_D^{25} = -106.1^\circ$ (c = 1, chloroform) containing the (-) enantiomer related to the (+) enantiomer in a ratio of
35 87:13 (based on HPLC analysis).

- 8 -

After recrystallizing the primary product from 52 ml of ethyl acetate, 2.80 g (55.6 %) of the aimed product were obtained, $[\alpha]_D^{25} = -153.6^\circ$ ($c = 1$, chloroform), m.p.: 170-172 °C. This product contained the minor enantiomer
5 in an amount lower than 1 % (based on HPLC analysis).

Method C

To a solution containing 4.75 g (18.6 mmol) of (S)-
-(-)-2-amino-1,1-diphenyl-3-methylbutan-1-ol in 50 ml of
dry dichloroethane, 9.5 ml (17 mmol) of an 1.8 M tetra-
10 hydrofuran solution of the borane-tetrahydrofuran complex
were dropwise added at -10 °C under dry nitrogen during
20 minutes. The solution was maintained at +4 °C for 15
hours, then 5.0 g (15.5 mmol) of 1-(4-nitrophenyl)-4-
methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine dissolved
15 in 200 ml of dry dichloroethane were dropwise added dur-
ing 1 hour while stirring. The reaction mixture obtained
was stirred at 60 °C for 30 hours. Thereafter, method A
of Example 1 was followed to obtain 4.2 g (83.3 %) of
primary product, $[\alpha]_D^{25} = -106.6^\circ$ ($c = 1$, chloroform).

20 In this product the ratio of the (-) enantiomer to
the (+) enantiomer was found to be 87:13 (based on HPLC
analysis).

By recrystallizing as described under method A of
Example 1, the primary product could be converted to the
25 aimed product having the enantiomeric purity given there.

Method D

By using 10.0 g (37.2 mmol) of (S)-(-)-2-amino-1,1-
-diphenyl-4-methyl-pentan-1-ol and 19 ml (34 mmol) of an
1.8 M tetrahydrofuran solution of borane-tetrahydrofuran
30 complex as starting substances and following the process
described under method A of Example 1, 4.2 g (83.3 %) of
primary product were obtained, $[\alpha]_D^{25} = -142.1^\circ$ ($c = 1$,
chloroform), which contained the (-) enantiomer related
to the (+) enantiomer in a 93:7 ratio (based on HPLC
35 analysis).

- 9 -

Method E

Method A of Example 1 was followed, except that 1.6 ml (17 mmol) of borane-dimethyl sulfide complex were used and the reaction mixture was allowed to stand at room temperature for 4 days to obtain 4.0 g (79.3 %) of primary product, $[\alpha]_D^{25} = -106.3^\circ$ (c = 1, chloroform), which contained the (-) enantiomer related to the (+) enantiomer in an 87:13 ratio (based on HPLC analysis).

Example 2**Method A**

(+)-1-(4-Nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

By using 4.75 g (18.6 mmol) of (R)-(+)-2-amino-1,1-diphenyl-3-methyl-butan-1-ol as starting substance and then following method A of Example 1, 4.61 g (91.4 %) of primary product were obtained, $[\alpha]_D^{25} = +112^\circ$ (c = 1, chloroform), which contained the (+) enantiomer related to the (-) enantiomer in an about 9:1 ratio (based on HPLC analysis).

After recrystallizing the primary product as described in Example 1, 3.1 g (61.3 %) of the aimed compound were obtained, $[\alpha]_D^{25} = +153.4^\circ$ (c = 1, chloroform), m.p.: 172-174 °C. This product contained the minor enantiomer in an amount lower than 1% (based on $^1\text{H-NMR}$ shift reagent as well as HPLC analysis).

Method B

Method C of Example 1 was followed by starting from 5.0 g (18.6 mmol) of (R)-(+)-2-amino-1,1-diphenyl-4-methylpentan-1-ol and using 1.6 ml (17 mmol) of borane-dimethyl sulfide complex, except that the reaction mixture was stirred at 60 °C for 3 hours to give 4.17 g (82.7 %) of primary product, $[\alpha]_D^{25} = +140.6^\circ$ (c = 1, chloroform), which contained the (+) enantiomer related to the (-) enantiomer in a 93:7 ratio (based on HPLC analysis).

- 10 -

By recrystallizing the primary product from 78 ml of hot ethyl acetate, 3.05 g (60.5 %) of the title compound were obtained, $[\alpha]_D^{25} = +155.2^\circ$ ($c = 1$, chloroform), m.p.: 172-174 °C, which contained the minor enantiomer in an amount lower than 1% (based on $^1\text{H-NMR}$ shift reagent as well as HPLC analysis).

The therapeutically valuable products may be prepared from the enantiomers of formula (I) according to the invention e.g. in the following way.

10 1. Preparation of (+)-1-(4-aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

Step a)

15 (-)-1-(4-Nitrophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

A suspension containing 2.34 g (7.2 mmol) of (-)-1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine in 11.7 ml of acetic anhydride was stirred at room temperature for 2 hours. Subsequently, the reaction solution was mixed with 60 ml of water under cooling with ice, the precipitate was filtered, washed 3 times with water and dried at 80 °C to obtain 2.5 g (94.6 %) of the aimed product, $[\alpha]_D^{25} = -54.9^\circ$ ($c = 1$, chloroform), m.p.: 172-177 °C.

25 Step b)

(+)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

To a suspension containing 2.6 g (7.08 mmol) of (-)-1-(4-nitrophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine in 52 ml of methanol, 0.5 g of wet Raney nickel catalyst and 1.2 ml (24.8 mmol) of 100% hydrazine hydrate were added and the reaction mixture was stirred for 1 hour. During this time a solution was formed and the inner temperature increased to 40-45 °C.

- 11 -

After filtration the catalyst was washed 3 times with 10 ml of methanol each, the filtrate was evaporated under reduced pressure and the residue was thoroughly triturated with 50 ml of water. The solidified crude

5 product was filtered, washed 3 times with 10 ml of water each and dried to give 2.17 g (90.8 %) of a product which was recrystallized from 14 ml of 50% aqueous ethanol to give 1.92 g (80.4 %) of the aimed product, $[\alpha]_D^{25} = +344.5^\circ$ ($c = 1$, methanol), m.p.: 168-170 °C.

10 This product contained the minor enantiomer in an amount lower than 1% [based on $^1\text{H-NMR}$ shift reagent method: 4.8 mg of the compound + 8.2 mg of $\text{Eu}(\text{hfc})_3$ shift reagent in deuterochloroform; or based on HPLC analysis (CHIRALCEL OF) by using an 1:1 mixture of hexane and iso-
15 propanol containing 0.1 % by vol. of diethylamine as eluent].

2. Preparation of (-)-1-(4-aminophenyl)-3-acetyl-4-
-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-
-benzodiazepine

20 Step a)

(+)-1-(4-Nitrophenyl)-3-acetyl-4-methyl-7,8-
-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

The title product was prepared by using (+)-(4-
-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-
25 -2,3-benzodiazepine as starting substance and following the method described in step 1.a) to give a yield of 92.7 %, $[\alpha]_D^{25} = +49.6^\circ$ ($c = 1$, chloroform), m.p.: 173-177 °C.

Step b)

30 (-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-
-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

By using (+)-1-(4-nitrophenyl)-3-acetyl-4-methyl-
-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine as
starting substance and following step 1.b), the crude
product was obtained in a yield of 91.3 %. This was
35 recrystallized from 50 % aqueous ethanol to give a yield

- 12 -

of 77.5%, $[\alpha]_D^{25} = -325.8^\circ$ ($c = 1$, methanol), m.p.: 167-170 °C. This product contained the minor enantiomer in an amount lower than 1% (based on $^1\text{H-NMR}$ or HPLC analysis).

5 3. Preparation of (+)-1-(4-Aminophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

Step a)

10 (-)-1-(4-Nitrophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

A mixture containing 4.0 g (12.3 mmol) of (-)-1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine, 2.18 ml (37 mmol) of methyl isocyanate and 80 ml of dry methylene chloride was stirred
15 at room temperature for 3 days. Then the solution was evaporated under reduced pressure and the residue was solidified by thoroughly triturating with 60 ml of water.

After filtration the product was washed and dried to obtain 4.49 g (95.5 %) of the aimed product, $[\alpha]_D^{25} =$
20 $= -315.3^\circ$ ($c = 1$, chloroform).

Step b)

25 (+)-1-(4-Aminophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

The title product was prepared by using (-)-1-(4-nitrophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine as
starting substance and following the process described in
step 1.b) to obtain a product with a yield of 95.14%,
30 $[\alpha]_D^{25} = +363.4^\circ$ ($c = 1$, chloroform).

This product contained the minor enantiomer in an amount lower than 1% (based on HPLC analysis and $^1\text{H-NMR}$ shift reagent method).

35 4. Preparation of (-)-1-(4-aminophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-

- 13 -

-dihydro-5H-2,3-benzodiazepine

Step a)

(+)-1-(4-Nitrophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

5 The aimed product was obtained in a yield of 95.0% by using (+)-1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine as starting substance and following the method described in step 10 3.a), $[\alpha]_D^{25} = +304.1^\circ$ (c = 1, chloroform).

Step b)

(-)-1-(4-Aminophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

15 The aimed product was prepared by using (+)-1-(4-nitrophenyl)-3-(N-methylcarbamoyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine as starting substance and following the method described in step 1.b) to give a yield of 95.5%, $[\alpha]_D^{25} = -365.9^\circ$ (c = 1, 20 chloroform).

This product contained the minor enantiomer in an amount lower than 1% (HPLC: CHIRALCEL OF by using a 1:1 mixture of n-hexane and isopropanol containing 0.1% by vol. of diethylamine as eluent; $^1\text{H-NMR}$: 10 ml of product + 25 + 10 or 20 mg of Eu(hfc)_3 shift reagent in deuteriochloroform).

5. Preparation of (-)-1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine

30 The aimed product was prepared by using (-)-1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine as starting substance and following the process described in step 1.b) to obtain a crude product in a yield of 82.0%, which was recrystallized 35 from 50% aqueous ethanol to give the aimed product,

- 14 -

$[\alpha]_D^{25} = -250.6^\circ$ ($c = 1$, methanol), m.p.: 98-100 °C. This product contained the minor enantiomer in an amount lower than 1% (based on HPLC analysis).


5 **6. Preparation of (+)-1-(4-aminophenyl)-4-methyl-
-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzo-
diazepine**

The aimed product was obtained in a yield of 80.9% by using (+)-1-(4-nitrophenyl)-4-methyl-7,8-methylene-dioxy-3,4-dihydro-5H-2,3-benzodiazepine as starting
10 substance and following the process described in step 1.b). It was purified by recrystallization from 50% aqueous ethanol to give a pure product, $[\alpha]_D^{25} = +246.0^\circ$ ($c = 1$, methanol), m.p.: 92-94 °C. This product contained
15 HPLC analysis).

- 15 -

Claims

1. Enantiomers of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of formula (I)




(I)

2. (-)-1-(4-Nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine.

3. (+)-1-(4-Nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine.


4. A process for the preparation of enantiomers of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine of formula (I), which comprises reducing 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine of formula (II)



(II)

- by using an adduct formed from an (R)- or (S)-, respectively, 2-amino-1,1-diphenyl-alkan-1-ol derivative of the general formula (III),

- 16 -



(III)

5

wherein R_1 and R_2 , which are different, stand for a straight or branched chain C_{1-4} alkyl group or an unsubstituted phenyl or benzyl group, with one molar equivalent of borane or a borane complex.

10 5. A process as claimed in claim 4, which comprises using (R)- or (S)-, respectively, 2-amino-1,1-diphenyl-3-methylbutan-1-ol as 2-amino-1,1-diphenyl-
15 alkan-1-ol of general formula (III).

6. A process as claimed in claim 4, which comprises using (R)- or (S)-, respectively, 2-amino-1,1-diphenyl-4-methylpentan-1-ol as 2-amino-1,1-diphenyl-
alkan-1-ol of general formula (III).

20 7. A process as claimed in any of claims 4 to 6, which comprises using a C_{1-4} aliphatic halo-hydrocarbon, preferably methylene chloride or 1,2-dichloroethane, as solvent.

8. A process as claimed in any of claims 4 to 7,
25 which comprises carrying out the reaction at a temperature between 10 °C and 100 °C, preferably between 25 °C and 60 °C.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/HU 94/00024

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 07 D 491/056; A 61 K 31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 07 D 491/056

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC, CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | DE, A, 3 727 226 (BIOGAL GYOGYSZERGYAR) 18 February 1988 (18.02.88), claims 1-8. | 1-8 |
| A | WO, A, 92/11 262 (GYOGYSZERKUTATO INTEZET) 09 July 1992 (09.07.92), claims 1-11. | 1-8 |
| A | EP, A, 0 492 485 (GYOGYSZERKUTATO INTEZET) 01 July 1992 (01.07.92), claims 1-7. (cited in the application) | 1-8 |
| | ---- | |

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 November 1994 (28.11.94)

Date of mailing of the international search report

06 December 1994 (06.12.94)

Name and mailing address of the ISA/AT
 AUSTRIAN PATENT OFFICE
 Kohlmarkt 8-10
 A-1014 Vienna
 Facsimile No. 1/53424/535

Authorized officer

Brus e.h.

Telephone No. 1/5337066/32

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/HU 94/00024

| Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche | Datum der Veröffentlichung Publication date Date de publication | Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets | Datum der Veröffentlichung Publication date Date de publication |
|--|--|--|--|
| DE A1 3727226 | 18-02-88 | AT A 2021/87 AU A1 76880/87 AU B2 596206 BE AE 1002415 CA A1 1284322 CH A 673652 CS A2 8706007 CS B2 264150 DD A5 265627 DK A0 4248/87 DK A 4248/87 DK B 164555 DK C 164555 ES AF 2004985 FI A0 873525 FI A 873525 FI B 85706 FI C 85706 FR A1 2602773 FR B1 2602773 GB A0 8719265 GB A1 2194236 GB B2 2194236 HU A2 47287 HU B 198494 IT A0 8721667 IT A 1222508 JP A2 63099073 NL A 8701909 NO A0 873426 NO A 873426 NO B 164656 NO C 164656 PL A1 276326 PL B1 148535 SE A0 8703169 SE A 8703169 SE B 467357 SE C 467357 SU A3 1779251 US A 4835152 YU A 1514/87 | 15-06-93 18-02-88 26-04-90 05-02-91 21-05-91 30-03-90 16-08-88 13-06-89 08-03-89 14-08-87 16-02-88 13-07-92 30-11-92 16-02-89 14-08-87 16-02-88 14-02-92 25-05-92 19-02-88 02-11-90 23-09-87 02-03-88 21-03-90 28-02-89 30-10-89 14-08-87 05-09-90 30-04-88 01-03-88 14-08-87 16-02-88 23-07-90 31-10-90 21-07-88 31-10-89 14-08-87 16-02-88 06-07-92 29-10-92 30-11-92 30-05-89 31-12-88 |
| WO A1 9211262 | 09-07-92 | AU A1 91226/91 CA AA 2098291 EP A1 565557 HU A0 908397 HU A2 59683 HU B 206719 JP T2 6506442 | 22-07-92 22-06-92 20-10-93 29-07-91 29-06-92 28-12-92 21-07-94 |
| EP A1 492485 | 01-07-92 | AU A1 89963/91 AU B2 641578 BR A 9105517 CA AA 2057504 CN A 1062730 CZ A3 9103985 FI A0 916032 FI A 916032 HU A0 908398 HU A2 59684 IL A0 100449 JP A2 5070463 MX A1 9102734 NO A0 915060 NO A 915060 NZ A 241110 ZA A 9110064 | 25-06-92 23-09-93 01-09-92 22-06-92 15-07-92 19-01-94 20-12-91 22-06-92 29-07-91 29-06-92 06-09-92 23-03-93 10-08-92 20-12-91 22-06-92 27-04-94 28-10-92 |